Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights Mar 29, 2023
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023 Mar 22, 2023
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial Mar 16, 2023
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates Mar 08, 2023
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy Mar 02, 2023
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Mar 02, 2023
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Feb 21, 2023
